Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

December-12-01

New Drug May Be Effective in Treating Breast Cancer

Studies presented at the San Antonio Breast Cancer Symposium indicate that a new class of hormone therapy may replace Tamoxifen in the treatment of certain types of breast cancers. In post-menopausal women with locally advanced or metastatic breast cancer and also in post-menopausal women with estrogen-receptor and HER-2 positive breast cancer, data suggests that Femara, a drug developed by the Swiss Pharmaceutical company Novartis, is more effective than the commonly used Tamoxifen in shrinking tumor growth. More importantly, in randomized-double blind studies, paid for in part by Novartis, Femara offered a better survival advantage than Tamoxifen. Side effects are essentially the same for both drugs. Femara is an aromatase inhibitor, a drug that prevents the hormone androgen from being converted to estrogen. Tamoxifen is an anti-estrogen, a drug that blocks the effects of already-existing estrogen from exerting its effects at the cellular level.

Research indicates that all breast cancer is not created equal. Future treatment plans will become more and more individually tailored as scientific advancements reveal more about the particulars of certain types of breast cancer. Therefore, it is critical that basic research and clinical trials continue in order to provide maximal therapeutic options for all women.

The Feminist Majority Foundation has launched an emergency campaign for mifepristone (also known as RU-486 and the abortion pill), an important anti-progesterone drug that blocks the effects of progesterone, at the cellular level. Preliminary studies indicate that mifepristone may be effective in treating certain types of breast cancer. Much basic research and clinical trials have come to a standstill however because anti-abortion forces have made it extremely difficult for scientists to even procure the drug to explore its exciting non-abortion medical potential.

Media Resources: Novartis; Associated Press, 12/11/01; Feminist Majority Foundation


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

7/29/2014 Extensive Female Genital Mutilation Study To Be Conducted in the US - The Obama administration plans to conduct a large study on female genital mutilation (FGM) to try to assess how many girls and women in the US are at risk, and how many have already experienced, FGM. According to experts, FGM tends to take place during summer break when parents take their daughter outside of the country for the practice. Jaha Dukureh, a 24-year-old woman who grew up in Gambia, experienced FGM there, and then child marriage in the US, started a petition that gained more than 220,000 supporters. . . .
 
7/29/2014 Three Anti-Abortion Extremists Sentenced In Mississippi - Last night, three of four anti-abortion extremists were found guilty by a Jackson, Miss. . . .
 
7/29/2014 Women Just Won Big In Mississippi - Feminist Majority Foundation leaders are elated by the Fifth Circuit Court of Appeals decision upholding a preliminary injunction against a Mississippi TRAP (Targeted Regulation of Abortion Provider) law that would have closed the only abortion clinic in the state. . . .